Sample Entry:
The International Biotechnology Directory

IBEX Technologies Inc 5485 Pare Street Montreal Quebec H4P 1P7 Canada Telephone 1 514 344-4004 Fax 1 514 344-8827 E-mail [email protected] IBEX Technologies was established in 1989 with its laboratories at the Biotechnology Research Institute in Montreal, Canada. Its then parent company, Continental/Pharma Cryosan, had been funding a research project at the Massachusetts Institute of Technology (MIT). IBEX Technologies was subsequently spun off and began to commercialise a line of products for cardiac surgery and haemodialysis. The company's main office is located in Montreal, Canada, with a satellite office (IBEX Technologies Corp) being located in Malvern, PA, USA. In July 1999, the company announced that a substantial part of its undertakings had been transferred to its wholly owned subsidiary, IBEX Pharmaceuticals. IBEX Pharmaceuticals is a biopharmaceutical company developing enzyme related therapeutics for the treatment of cardiovascular disease, tissue repair and genetic diseases of enzyme deficiency. The company's product candidates are derived from two technology platforms: GLE Technology and Oralase™ technology. The GLE technology is based on the production and development of proprietary glycosaminoglycan lyase enzymes. Patents covering the GLE technology have been licensed from MIT. The company has also received patents covering GLE technology derived from its own research efforts. The Oralase™ technology makes use of enzymes formulated to be orally deliverable, which decrease the availability and absorption of a specific amino acid from the intestinal tract. By modulating the concentration of the specific amino acid in the gut, blood levels of the amino acid can be controlled. The company's lead product candidate, Neutralase™ (heparinase 1), for the neutralisation of heparin following bypass surgery, is derived from GLE technology. Phase III clinical studies have been initiated at sites in the USA and Germany. The second therapeutic application of GLE technology is Extravase™ (IBT 9302/heparinase III). The therapeutic applications being investigated for Extravase™ include reperfusion injury following heart attack (myocardial infarction) and/or stroke, restenosis and wound healing. This product candidate is currently in the pre-Investigational New Drug (IND) stage of development. Other potential therapeutic applications of GLE technology, which are in the research stage, include PEG-heparinase III for the treatment of chronic inflammatory diseases, Chondroitinase AC for the treatment of metastatic cancers, Chondroitase B for the treatment of psoriasis and scleroderma. The lead product using the Oralase™ technology is Phenylase™ (phenylalanine ammonia lyase (PAL)) for use in treating phenylketonuria (PKU). Other applications of Oralase™ technology include oral delivery of enzymes for the depletion of amino acids necessary for the growth of various cancers (for example, asparaginase in the case of acute lymphoblastic leukaemia). Additional Notes Formerly Continental Pharma Cryosan Inc (CPCI)

Year founded 1989 Total staff 25 on 20/01/2000 Financial data for year ending 31/07/1999   Revenues: $935,000   Net profit (after tax): ($9.137M)   Research expenditure: $7.333M Stock exchanges [ticker symbols, if any] Toronto Stock Exchange (TSE) [IBT] Products and Services Therapeutic drugs Interest Areas Cardiology; Cell biology; Dermatology; Drug design/development; Enzymology; Genetic diseases; Human healthcare; Inflammation; Oncology/cancer; Pharmaceuticals; Surgery Key executives Mr Paul Baehr   Chairman and Chief Executive Officer (CEO) Dr Robert A Heft   President and Chief Operating Officer (COO)

© PJB Publications Ltd. 2000 All rights reserved.